A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash.

A 17-year-old white male with a 9-year history of ileocolonic Crohn's disease developed a skin rash while receiving infliximab, a chimeric IgG1κ monoclonal antibody against tumor necrosis factor ...

[20] In six of these patients infliximab was reintroduced with no ... Most patients with anti-TNF-induced rashes will give negative responses to these questions. As the response of the rash ...